Onc Now: Episode 5: The Role of RNA in Oncology – Part 2 - European Medical Journal

Onc Now: Episode 5: The Role of RNA in Oncology – Part 2

Oncology

Onc Now | Episode 5

Sarah Blagden, pioneer in experimental oncology, returns to the podcast to discuss cancer prediction and prevention, and the future of cancer vaccines.

Spotify | Apple | Amazon Music | Youtube | Download MP3 (35 mins)

Speaker bio: 

Sarah Blagden Headshot

Sarah Blagden is Professor of Experimental Oncology at the University of Oxford, where she leads pioneering research in cancer treatment and molecular biology. As head of the Experimental Oncology Research Group, Sarah focuses on innovative approaches to identify and target cancer at the molecular level. Her impact extends beyond academia: she is also the CEO of RNA Guardian Ltd, a biotechnology company committed to developing early cancer biomarkers that have the potential to transform cancer detection and patient outcomes. 

 

Timestamps:
  • 00:00 – Introduction
  • 00:35 – The mission of RNA Guardian Ltd
  • 02:02 – mTOR in cancer biology
  • 06:24 – Raising awareness of ovarian cancer
  • 08:32 – A new era of cancer prediction and prevention
  • 11:38 – The future of cancer vaccines
  • 15:58 – Advice to medical students: academia versus medicine
  • 19:42 – Sarah’s three wishes for healthcare

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given